NORFLEX
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Nov 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORFLEX is an oral extended-release tablet approved in 1959 for muscle relaxation, representing a legacy small-molecule product in the skeletal muscle relaxant category. The generic name and mechanism of action are not specified in available data, but the product serves as a standard-of-care option in musculoskeletal pain management.
LOE Approaching
As LOE approaches, commercial teams face declining exclusivity and generic competition, suggesting reduced headcount and shift toward cost-management and lifecycle extension strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NORFLEX offers minimal career growth prospects as a legacy, LOE-approaching product with zero linked job openings. Roles focus on defending market position, managing generic transition, and operational efficiency rather than innovation or expansion.
Brand Manager (Legacy)Field Sales Representative
Worked on NORFLEX at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.